Initial Experience with Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction  

作　　者：Heyi Zhen Tianhai Huang Xiaoyi Yang Qiuling Liu Qingqing Li Maping Huang Hui Chen Heyi Zhen;Tianhai Huang;Xiaoyi Yang;Qiuling Liu;Qingqing Li;Maping Huang;Hui Chen(Department of Traumatic Brain Injury Rehabilitation, Guangdong Province Work Injury Rehabilitation Hospital, Guangzhou, China;Department of Urology, Guangdong Provincial Work Injury Rehabilitation Hospital, Guangzhou, China)

机构地区：[1]Department of Traumatic Brain Injury Rehabilitation, Guangdong Province Work Injury Rehabilitation Hospital, Guangzhou, China [2]Department of Urology, Guangdong Provincial Work Injury Rehabilitation Hospital, Guangzhou, China

出　　处：《Open Journal of Urology》2021年第8期305-311,共7页泌尿学期刊（英文）

摘　　要：<strong>Background: </strong>Though anticholinergic drugs are considered the standard treatment for neurogenic detrusor overactivity, it is far from an ideal tool, because of their adverse effects such as Constipation or not respond sufficiently for a substantial proportion of patients. Recently mirabegron has become a commonly used overactive bladder medication in the general population, but few studies about mirabegron for the treatment of neurogenic detrusor overactivity. <strong>Objective:</strong> To evaluate the efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction. <strong>Study Design:</strong> Prospective study. <strong>Methods:</strong> This prospective study included 13 adult patients with neurogenic lower urinary tract dysfunction as a result of spinal cord injury. All patients receiving mirabegron treatment (50 mg once daily) at least 6 weeks. The effective outcomes included the mean urine volume per catheterization, urinary incontinence episodes and Incontinence Specific Quality of Life Instrument. We monitored the blood pressure and heart rate to assess the cardiovascular safety, other adverse events were also recorded. <strong>Results:</strong> A total of 13 patients were included. After 6 weeks of treatment, all patients experienced a significant increase in the mean volume of per catheterization from 238.46 ± 65.43 ml to 327.69 ± 59.04 ml (p = 0.001). There is a significant reduction in the volume of urine leakage (463.85 ± 247.98 ml VS 180.00 ± 190.96 ml, p = 0.003) and incontinence episodes per 24 h (4.46 ± 2.03 VS 1.92 ± 1.50, p = 0.001). Significant improvement in mean Incontinence Specific Quality of Life Instrument was also found (p = 0.001). No patients reported dry mouth during the study, and the cardiovascular safety were acceptable. <strong>Conclusion:</strong> Mirabegron is safe and effective in the treatment of neurogenic lower urinary tract dysfunction. It might be a good choice for reducing the cessation of clean intermittent cathet<strong>Background: </strong>Though anticholinergic drugs are considered the standard treatment for neurogenic detrusor overactivity, it is far from an ideal tool, because of their adverse effects such as Constipation or not respond sufficiently for a substantial proportion of patients. Recently mirabegron has become a commonly used overactive bladder medication in the general population, but few studies about mirabegron for the treatment of neurogenic detrusor overactivity. <strong>Objective:</strong> To evaluate the efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction. <strong>Study Design:</strong> Prospective study. <strong>Methods:</strong> This prospective study included 13 adult patients with neurogenic lower urinary tract dysfunction as a result of spinal cord injury. All patients receiving mirabegron treatment (50 mg once daily) at least 6 weeks. The effective outcomes included the mean urine volume per catheterization, urinary incontinence episodes and Incontinence Specific Quality of Life Instrument. We monitored the blood pressure and heart rate to assess the cardiovascular safety, other adverse events were also recorded. <strong>Results:</strong> A total of 13 patients were included. After 6 weeks of treatment, all patients experienced a significant increase in the mean volume of per catheterization from 238.46 ± 65.43 ml to 327.69 ± 59.04 ml (p = 0.001). There is a significant reduction in the volume of urine leakage (463.85 ± 247.98 ml VS 180.00 ± 190.96 ml, p = 0.003) and incontinence episodes per 24 h (4.46 ± 2.03 VS 1.92 ± 1.50, p = 0.001). Significant improvement in mean Incontinence Specific Quality of Life Instrument was also found (p = 0.001). No patients reported dry mouth during the study, and the cardiovascular safety were acceptable. <strong>Conclusion:</strong> Mirabegron is safe and effective in the treatment of neurogenic lower urinary tract dysfunction. It might be a good choice for reducing the cessation of clean intermittent cathet

关 键 词：Neurogenic Lower Urinary Tract MIRABEGRON Detrusor Overactivity Spinal Cord Injury 

分 类 号：R98[医药卫生—药品]